Evidence map›Paper›PMID 41332664›Full record

ArticlebioRxiv : the preprint server for biology2025

Proteogenomic profiling of soft tissue leiomyosarcoma reveals distinct molecular subtypes with divergent outcomes and therapeutic vulnerabilities.

Atsushi Tanaka, Makiko Ogawa, Yusuke Otani, Ronald C Hendrickson, Zhuoning Li, Narasimhan P Agaram, David S Klimstra, Julia Y Wang, Michael H A Roehrl

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Atsushi TanakaDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Makiko OgawaDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Yusuke OtaniDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Ronald C HendricksonDepartment of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Zhuoning LiSloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Narasimhan P AgaramDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David S KlimstraFormer address: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Julia Y WangCurandis, Boston, MA, USA.
Michael H A RoehrlDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology PatientsU01CA263986 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Wenyi Wei · 2022 to 2026
$1.3M
Proteomic Characterization of Genomically Complex SarcomasR21CA251992 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROEHRL, MICHAEL H. A. · 2020 to 2020
$487k
Proteomic Characterization of Pancreatic Neuroendocrine Tumors and Metastatic ProgressionR21CA263262 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROEHRL, MICHAEL H. A. · 2021 to 2022
$450k
NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA251992NCI NIH HHS R21 CA263262NCI NIH HHS U01 CA263986
6 · The paper itself

Abstract

Soft tissue leiomyosarcoma (STLMS) is an aggressive malignancy lacking validated molecular subclassification and effective targeted treatments. We performed comprehensive proteogenomic analysis of primary and metastatic STLMS to uncover biological traits and therapeutic weaknesses. Integrative proteomic and phosphoproteomic analyses using non-negative matrix factorization identified three subtypes. Subtype P1 shows genomic stability, low proliferation, and enrichment of FGFR2 and PDK signaling pathways. Subtype P2 exhibits chromosomal instability, inflammatory programs, activation of CDK-AURKA/B-mTOR/ERK kinome with

Identifiers

PMID41332664
PMCPMC12667925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.